McMeekin S - Search Results

1

Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. Dao F, et al. Among authors: mcmeekin s. Gynecol Oncol. 2016 May;141(2):260-263. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11. Gynecol Oncol. 2016. PMID: 26968641 Free PMC article.

2

Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary.

Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, Bloss LP, DiSaia PJ. Bloss JD, et al. Among authors: mcmeekin s. Gynecol Oncol. 1993 Sep;50(3):347-51. doi: 10.1006/gyno.1993.1223. Gynecol Oncol. 1993. PMID: 8406199

3

Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients.

Wang Y, Thai T, Moore K, Ding K, McMeekin S, Liu H, Zheng B. Wang Y, et al. Among authors: mcmeekin s. Oncol Lett. 2016 Jul;12(1):680-686. doi: 10.3892/ol.2016.4648. Epub 2016 May 31. Oncol Lett. 2016. PMID: 27347200 Free PMC article.

4

Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis.

Qiu Y, Tan M, McMeekin S, Thai T, Ding K, Moore K, Liu H, Zheng B. Qiu Y, et al. Among authors: mcmeekin s. Acta Radiol. 2016 Sep;57(9):1149-55. doi: 10.1177/0284185115620947. Epub 2015 Dec 11. Acta Radiol. 2016. PMID: 26663390 Free PMC article.

5

Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.

Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM, Fung KM. Zakharov V, et al. Among authors: mcmeekin s. Int J Clin Exp Pathol. 2010 Jul 5;3(6):608-17. Int J Clin Exp Pathol. 2010. PMID: 20661409 Free PMC article.

6

MICU1 drives glycolysis and chemoresistance in ovarian cancer.

Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, Moore K, McMeekin S, Yang D, Zuna R, Ding K, Tsiokas L, Bhattacharya R, Mukherjee P. Chakraborty PK, et al. Among authors: mcmeekin s. Nat Commun. 2017 May 22;8:14634. doi: 10.1038/ncomms14634. Nat Commun. 2017. PMID: 28530221 Free PMC article.

7

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.

Pant S, Burris HA 3rd, Moore K, Bendell JC, Kurkjian C, Jones SF, Moreno O, Kuhn JG, McMeekin S, Infante JR. Pant S, et al. Among authors: mcmeekin s. Invest New Drugs. 2014 Feb;32(1):87-93. doi: 10.1007/s10637-013-9949-4. Epub 2013 Mar 24. Invest New Drugs. 2014. PMID: 23525756 Free PMC article. Clinical Trial.

8

A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration.

Tan M, Li Z, Qiu Y, McMeekin SD, Thai TC, Ding K, Moore KN, Liu H, Zheng B. Tan M, et al. IEEE Trans Med Imaging. 2016 Jan;35(1):316-25. doi: 10.1109/TMI.2015.2473823. Epub 2015 Aug 27. IEEE Trans Med Imaging. 2016. PMID: 26336119 Free PMC article.

9

Donato ML, Levenback C, Gershenson DM, McMeekin S, Champlin RE. Donato ML, et al. Among authors: mcmeekin s. Gynecol Oncol. 2004 Jan;92(1):365-7. doi: 10.1016/j.ygyno.2003.09.004. Gynecol Oncol. 2004. PMID: 14751187

10

Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment.

Srivastava A, Filant J, Moxley KM, Sood A, McMeekin S, Ramesh R. Srivastava A, et al. Among authors: mcmeekin s. Curr Gene Ther. 2015;15(2):182-92. doi: 10.2174/1566523214666141224100612. Curr Gene Ther. 2015. PMID: 25537774 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters